Compugen (CGEN) AI Stock Analysis

• Market Cap: $185.20M
• Dividend Yield: N/A
• Average Volume (3M): 445.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -88.47%
• EPS Growth: -1658.33%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 93,535,355
• 10 Day Avg. Volume: 543,941
• 30 Day Avg. Volume: 445,520
• PEG Ratio: 0.40
• Price to Book (P/B): 2.49
• Price to Sales (P/S): 4.92
• P/FCF Ratio: 2.77
• Enterprise Value/Market Cap: 0.29
• Enterprise Value/Revenue: 7.25
• Enterprise Value/Gross Profit: 8.33
• Enterprise Value/Ebitda: -1.67
• 1Y Price Target: $4.00
• Price Target Upside: 89.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.17
• Revenue Forecast (FY): $22.41M

• Rating: 52 Neutral
• Price Target: $2.00 ▼(-5.21% Downside)

Compugen's overall stock score is primarily influenced by its financial performance and technical analysis. The company's strategic partnerships and potential future milestones provide some optimism, but current financial challenges and valuation concerns weigh heavily on the score.

Positive Factors

Strategic Partnerships

The partnership with AstraZeneca provides significant revenue potential through milestone payments and royalties, enhancing long-term financial stability.

Cash Flow Improvement

Improved cash flow management indicates better financial health, providing Compugen with more resources to invest in R&D and strategic initiatives.

Pipeline Advancements

Focus on innovative therapies like Fc reduced anti-TIGIT programs positions Compugen to potentially lead in new treatment areas, driving future growth.

Negative Factors

Revenue Decline

A significant revenue decline indicates challenges in sustaining financial performance, potentially impacting long-term operational stability.

Extended Clinical Timelines

Extended timelines for clinical trials could delay product launches and revenue generation, affecting Compugen's growth trajectory.

Net Loss

Ongoing net losses highlight financial challenges and may limit Compugen's ability to invest in growth opportunities, impacting long-term viability.

Compugen Business Overview & Revenue Model

Company Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

How the Company Makes Money

Compugen generates revenue primarily through collaborations, licensing agreements, and research grants. The company partners with major pharmaceutical companies to co-develop its drug candidates, receiving upfront payments, milestone payments, and royalties on future sales. These partnerships are a key revenue stream, as they provide funding for research and development while sharing the financial risks associated with bringing new therapies to market. Additionally, Compugen may receive funding through government grants aimed at supporting innovative medical research, further contributing to its earnings.

Compugen Financial Statement Overview

Summary

Compugen's financial performance reflects typical challenges in the biotechnology sector, with fluctuating revenue growth and consistent profitability issues. Despite improvements in cash flow management, the company faces risks in sustaining profitability and maintaining financial stability.

Income Statement

Compugen has shown fluctuating revenue growth, with a positive increase from 2021 to 2023 but a decline in 2024. The consistent negative net income and EBIT margins reflect ongoing challenges in profitability, typical in the biotechnology sector. Despite improvements in gross profit, the company's net profit margins remain negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals a stable equity position but high volatility in debt levels. The debt-to-equity ratio remains low, suggesting manageable leverage. However, the declining equity ratio and fluctuations in stockholders' equity indicate potential risks in maintaining financial stability.

Cash Flow

Cash flow analysis shows significant improvement in operating cash flow and free cash flow by 2024, highlighting better cash management. However, the company experienced negative free cash flow in previous years, raising concerns about long-term cash sustainability. The positive cash flow trend in 2024 is a promising sign of recovery.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.50M	27.86M	33.46M	7.50M	6.00M	2.00M
Gross Profit	6.53M	19.93M	31.45M	6.53M	5.32M	1.94M
EBITDA	-32.58M	-14.40M	-12.52M	-33.13M	-34.61M	-28.94M
Net Income	-31.56M	-14.23M	-18.75M	-33.69M	-34.20M	-29.70M
Balance Sheet
Total Assets	67.61M	115.00M	121.33M	94.18M	132.16M	138.32M
Cash, Cash Equivalents and Short-Term Investments	57.51M	103.25M	50.69M	83.71M	117.76M	123.77M
Total Debt	1.41M	2.91M	1.35M	1.93M	2.75M	3.17M
Total Liabilities	14.38M	60.08M	55.77M	16.50M	25.47M	18.53M
Stockholders Equity	53.23M	54.91M	65.56M	77.68M	106.69M	119.78M
Cash Flow
Free Cash Flow	-23.38M	49.49M	-36.06M	-34.99M	-23.04M	-28.49M
Operating Cash Flow	-23.03M	49.60M	-35.89M	-34.51M	-22.75M	-28.32M
Investing Cash Flow	40.39M	-46.25M	35.51M	37.06M	6.62M	-82.17M
Financing Cash Flow	-18.41M	554.00K	3.08M	353.00K	16.84M	108.46M

Compugen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEN, the sentiment is Positive. The current price of 2.11 is above the 20-day moving average (MA) of 1.65, above the 50-day MA of 1.62, and above the 200-day MA of 1.56, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 76.58 is Negative, neither overbought nor oversold. The STOCH value of 87.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGEN.

Compugen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVCT	54 Neutral	$215.42M	-6.46	-158.88%	―	―	-16.26%
STTK	53 Neutral	$299.31M	-4.38	-57.84%	―	-84.46%	33.32%
CGEN	52 Neutral	$185.20M	-7.05	-52.95%	―	-88.47%	-1658.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	48 Neutral	$147.03M	-1.41	-26.69%	―	―	25.84%
CCCC	44 Neutral	$225.81M	-1.33	-59.98%	―	-10.57%	1.98%
ELTX	43 Neutral	$140.44M	-2.30	―	―	―	17.36%

Compugen Corporate Events

Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca

On December 16, 2025, Compugen Ltd. amended its license agreement with AstraZeneca, monetizing a portion of future royalties from rilvegostomig for an upfront payment of $65 million and a potential milestone payment of $25 million. This strategic transaction strengthens Compugen’s financial position, extending its cash runway to 2029, allowing funds to be allocated towards advancing its innovative immuno-oncology pipeline, including internal and partnered programs. Retaining the majority of future royalties, Compugen preserves long-term upside from the potential success of rilvegostomig, developed by AstraZeneca as a promising cancer immunotherapy drug, which is undergoing robust Phase 3 trials across various types of cancer.

The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.

Compugen Reports Q3 2025 Results and Advances Clinical Trials

On November 10, 2025, Compugen Ltd. reported its third quarter 2025 financial results and provided a corporate update. The company highlighted the presentation of COM701 Phase 1 data at ESMO 2025, which informed the design of the ongoing MAIA-ovarian platform trial. Compugen is enrolling patients in the U.S., Israel, and France for this trial, with interim analysis expected in Q1 2027. The company also presented the Phase 1 trial design for GS-0321 at SITC 2025. Partner AstraZeneca shared promising results from Phase 2 trials of rilvegostomig in NSCLC and bladder cancer. Financially, Compugen reported a solid cash position expected to fund operations into Q3 2027, despite a net loss of $6.98 million for the quarter.

The most recent analyst rating on (CGEN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.